$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000161883520000216 Filed on August 04, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.73M	$6.695M
YoY Change	194.73%	-41.32%
% of Gross Profit
Research & Development	$2.640M	$5.246M
YoY Change	-49.68%	-55.67%
% of Gross Profit
Depreciation & Amortization	$50.00K	$60.00K
YoY Change	-16.67%	0.0%
% of Gross Profit
Operating Expenses	$22.37M	$11.94M
YoY Change	87.35%	-48.62%
Operating Profit	-$22.37M	-$11.94M
YoY Change	87.35%	-48.62%
Interest Expense	-$29.95M	-$23.50M
YoY Change	27.45%	-78433.33%
% of Operating Profit
Other Income/Expense, Net	-$30.29M	-$23.51M
YoY Change	28.88%
Pretax Income	-$52.67M	-$35.45M
YoY Change	48.58%	52.51%
Income Tax	$0.00	$4.000K
% Of Pretax Income
Net Earnings	-$52.67M	-$35.45M
YoY Change	48.56%	52.51%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.91
Diluted Earnings Per Share	-$0.91	-$965.2K
COMMON SHARES
Basic Shares Outstanding	57.70M shares	35.37M shares
Diluted Shares Outstanding	57.70M shares

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.7M	$50.70M
YoY Change	143.98%	122.37%
Cash & Equivalents	$123.6M	$50.68M
Short-Term Investments	$200.0K
Other Short-Term Assets	$2.000M	$1.900M
YoY Change	5.26%	46.15%
Inventory	$1.440M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$127.9M	$52.85M
YoY Change	141.99%	115.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.084M	$461.0K
YoY Change	135.14%	-35.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.067M	$622.0K
YoY Change	71.54%	-36.34%
Total Long-Term Assets	$7.166M	$1.566M
YoY Change	357.6%	-7.56%
TOTAL ASSETS
Total Short-Term Assets	$127.9M	$52.85M
Total Long-Term Assets	$7.166M	$1.566M
Total Assets	$135.1M	$54.42M
YoY Change	148.2%	107.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.421M	$8.567M
YoY Change	-1.7%	7.11%
Accrued Expenses	$2.597M	$7.217M
YoY Change	-64.02%	-35.01%
Deferred Revenue
YoY Change
Short-Term Debt	$44.30M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$61.81M	$18.62M
YoY Change	231.88%	-10.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.700M	$0.00
YoY Change
Total Long-Term Liabilities	$4.700M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$61.81M	$18.62M
Total Long-Term Liabilities	$4.700M	$0.00
Total Liabilities	$66.52M	$18.62M
YoY Change	257.18%	-10.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$585.0M	-$486.7M
YoY Change	20.21%	21.76%
Common Stock	$653.5M	$522.5M
YoY Change	25.09%	29.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$68.54M	$35.79M
YoY Change
Total Liabilities & Shareholders Equity	$135.1M	$54.42M
YoY Change	148.2%	107.94%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$52.67M	-$35.45M
YoY Change	48.56%	52.51%
Depreciation, Depletion And Amortization	$50.00K	$60.00K
YoY Change	-16.67%	0.0%
Cash From Operating Activities	-$15.05M	-$19.55M
YoY Change	-23.02%	1.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.050M	$0.00
YoY Change
Cash From Investing Activities	$1.050M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$103.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	128.5M	70.03M
YoY Change	83.56%	89.63%
NET CHANGE
Cash From Operating Activities	-15.05M	-19.55M
Cash From Investing Activities	1.050M	0.000
Cash From Financing Activities	128.5M	70.03M
Net Change In Cash	114.5M	50.48M
YoY Change	126.92%	184.55%
FREE CASH FLOW
Cash From Operating Activities	-$15.05M	-$19.55M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81280286	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	585000	USD
CY2020Q2	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	72000	USD
CY2019Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	0	USD
CY2020Q2	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	516000	USD
CY2019Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1300000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationOfPurchaseRightsLiability	22800000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Warrants AdjustmentsToAdditionalPaidinCapitalReclassificationOfWarrants	6900000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability	29726000	USD
CY2020Q2	evfm	Class Of Warrant Or Right Aggregate Principal Amount Of Securities Purchased ClassOfWarrantOrRightAggregatePrincipalAmountOfSecuritiesPurchased	10000000	USD
CY2020Q2	evfm	Class Of Warrant Or Right Liability ClassOfWarrantOrRightLiability	46700000	USD
CY2020Q1	evfm	Class Of Warrant Or Right Right Agreement Beneficial Ownership Threshold ClassOfWarrantOrRightRightAgreementBeneficialOwnershipThreshold	0.32
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	3781000	USD
	evfm	Proceeds From Short Swing Profit Disgorgement ProceedsFromShortSwingProfitDisgorgement	0	USD
CY2020Q1	evfm	Class Of Warrant Or Right Vesting Term ClassOfWarrantOrRightVestingTerm	P10D
	evfm	Proceeds From Short Swing Profit Disgorgement ProceedsFromShortSwingProfitDisgorgement	173000	USD
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2020Q2	evfm	Class Of Warrant Or Right Vesting Term ClassOfWarrantOrRightVestingTerm	P5Y
CY2020Q1	evfm	Class Of Warrant Or Right Vesting Term For Beneficial Ownership Threshold ClassOfWarrantOrRightVestingTermForBeneficialOwnershipThreshold	P10D
CY2020Q2	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	10426107	shares
CY2019Q2	evfm	Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned	1
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	257000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	550000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
CY2019Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19600000	USD
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	378000	USD
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	39000	USD
CY2020Q2	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	5	vehicle
	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	16	vehicle
CY2015Q1	evfm	Lessee Operating Lease Renewal Options LesseeOperatingLeaseRenewalOptions	2	renewal_term
CY2019Q2	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	674000	USD
	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	674000	USD
CY2020Q2	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	64049000	USD
CY2020Q2	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	64000000	USD
	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	64049000	USD
CY2019Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	700000	USD
CY2015Q4	evfm	Number Of Sublicenses NumberOfSublicenses	2	Agreement
CY2019Q4	evfm	Office Square Footage OfficeSquareFootage	24474	sqft
CY2020Q2	evfm	Office Square Footage OfficeSquareFootage	8816	sqft
	evfm	Periodic Release Of Security Deposit PeriodicReleaseOfSecurityDeposit	5000	USD
	evfm	Periodic Release Of Security Deposit PeriodicReleaseOfSecurityDeposit	66000	USD
CY2020Q2	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000	USD
CY2020Q2	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000.0	USD
CY2020Q2	evfm	Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities	100000000.0	USD
CY2019Q2	evfm	Purchase Right Liability PurchaseRightLiability	3200000	USD
	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	6120000	USD
	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	11015000	USD
CY2020Q2	evfm	Securities Sold Under Purchase Agreement SecuritiesSoldUnderPurchaseAgreement	15000000	USD
CY2020Q2	evfm	Short Swing Profit Disgorgement ShortSwingProfitDisgorgement	200000	USD
CY2020Q2	evfm	Short Swing Profit Disgorgement ShortSwingProfitDisgorgement	187000	USD
CY2020Q1	evfm	Stock Dividend Rights Issued Per Share Of Common Stock Held StockDividendRightsIssuedPerShareOfCommonStockHeld	1	shares
CY2020Q1	evfm	Stock Dividends Right StockDividendsRight	1	shares
CY2020Q2	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	177000	USD
CY2019Q2	evfm	Warrant Liability WarrantLiability	3600000	USD
CY2020Q2	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	66100000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6008000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8421000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2784000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2597000	USD
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	0	USD
CY2020Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	758000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1652000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	730000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	849000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	972000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	528810000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	653522000	USD
CY2019Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-6000	USD
CY2019Q2	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-518000	USD
CY2020Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-25000	USD
CY2020Q2	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-2777000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	11000000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	11015000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	15800000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1962000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2515000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3401000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6034000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2515000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4477000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6034000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9435000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13041564	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19062447	shares
CY2019Q4	us-gaap	Assets Assets	28295000	USD
CY2020Q2	us-gaap	Assets Assets	135056000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	26421000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	127890000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	22588000	USD
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	122413000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	278000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50679000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15571000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123556000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	123600000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1761000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51080000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124556000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	49319000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	107931000	USD
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.54
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0175
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.44
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.001	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10426107	shares
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	22969243	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48137880	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81300667	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48137880	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81300667	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2020Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	43958000	USD
CY2020Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	58100000	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	44302000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	132000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123000	USD
CY2019Q2	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
CY2020Q2	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.68
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.36
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3670000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5944000	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3300000	USD
CY2019Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22932000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-27372000	USD
CY2020Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	34100000	USD
CY2020Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	34075000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	34075000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5382000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10007000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9735000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16877000	USD
CY2019Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	8233000	USD
CY2020Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	0	USD
CY2019Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	42000	USD
CY2019Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	8275000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35446000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53514000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52666000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71812000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	12659000	USD
	us-gaap	Lease Cost LeaseCost	364000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	29000	USD
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	200000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	131000	USD
	us-gaap	Lease Cost LeaseCost	319000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	344000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	1440000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-478000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1697000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4176000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-563000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-665000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2274000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	872000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	985000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	853000	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1200000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	108000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	126000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	201000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7439000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	0	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1543000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1104000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1612000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1599000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1673000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	201000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	-92000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2186000	USD
CY2015Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P36M
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27941000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	22372000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30294000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30196000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	11941000	USD
	us-gaap	Operating Expenses OperatingExpenses	25573000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	66517000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28295000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135056000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12659000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	61806000	USD
CY2020Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	43958000	USD
CY2019Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2020Q2	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76295000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129912000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	250000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7947000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27226000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29928000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-18068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-35450000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53518000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19146000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-52666000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-71812000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23505000	USD
	us-gaap	Operating Expenses OperatingExpenses	41616000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11941000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25573000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22372000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-41616000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	186000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	377000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	352000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	532000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	197000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5253000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	197000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	542000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4711000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	427000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	225000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5015000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	547000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	521000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6273000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1243000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2056000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1084000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4010000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5246000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13135000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2640000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6887000	USD
CY2019Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	401000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1320000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1067000	USD
CY2019Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	21000	USD
CY2020Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	349000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	353000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	890000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	317000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	524000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2802000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	536000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2313000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2694000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103738000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	25000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75400000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	46000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	337000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8233000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	304000	USD
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	750000	USD
CY2020Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-584991000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-513179000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585000000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	802000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5219000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1313000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2431000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9997000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17852000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4477000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9435000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	384000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	443000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	767000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2242485	shares
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	103266000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	73000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-23356000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-28851000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	35792000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15636000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1021000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	68539000	USD
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36732568	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31941850	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57696519	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52946235	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:9pt;">S</font><font style="font-family:inherit;font-size:10pt;">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the discount rate used in estimating the fair value of the lease right-of-use (ROU) assets and lease liabilities, assumptions used in estimating the fair value of warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards. The Company’s assumptions regarding the measurement of the Private Placement First Closing Warrants, the Private Placement Second Closing Warrants, the Baker First Closing Warrants, the Baker Second Closing Warrants, the Private Placement Purchase Rights, the Baker Purchase Rights, the lease ROU assets and lease liabilities, and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#sEF4F9A1315D951018F77B4B11687E7A8"><font style="font-family:inherit;font-size:10pt;">Note 4- Convertible Notes</font></a><font style="font-family:inherit;font-size:10pt;">, </font><a style="font-family:inherit;font-size:10pt;" href="#sDB10BF7FE8365167B49EA5D19016BBA9"><font style="font-family:inherit;font-size:10pt;">Note 6- Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;">, </font><a style="font-family:inherit;font-size:10pt;" href="#s0DCBEE2CFD98586A8C179DC806D65B0B"><font style="font-family:inherit;font-size:10pt;">Note 7- Commitments and Contingencies</font></a><font style="font-family:inherit;font-size:10pt;">, and </font><a style="font-family:inherit;font-size:10pt;" href="#sEB35C3F521275375A840EA9E8A07088B"><font style="font-family:inherit;font-size:10pt;">Note 11- Stock-based Compensation</font></a><font style="font-family:inherit;font-size:10pt;">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-20-000216-index-headers.html	Edgar Link	pending
0001618835-20-000216-index.html	Edgar Link	pending
0001618835-20-000216.txt	Edgar Link	pending
0001618835-20-000216-xbrl.zip	Edgar Link	pending
evfm-20200630.xml	Edgar Link	completed
evfm-20200630.xsd	Edgar Link	pending
evfm-20200630_cal.xml	Edgar Link	unprocessable
evfm-20200630_def.xml	Edgar Link	unprocessable
evfm-20200630_lab.xml	Edgar Link	unprocessable
evfm-20200630_pre.xml	Edgar Link	unprocessable
evfm-630202010xq.htm	Edgar Link	pending
evfm-6302020ex311.htm	Edgar Link	pending
evfm-6302020ex312.htm	Edgar Link	pending
evfm-6302020ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2020 Q2 Form 10-Q Financial Statement

#000161883520000216 Filed on August 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2020 Q2 Form 10-Q Financial Statement

#000161883520000216 Filed on August 04, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm